- Sweden
- /
- Healthtech
- /
- OM:CARA
Carasent Second Quarter 2025 Earnings: kr0.08 loss per share (vs kr0.079 loss in 2Q 2024)
Carasent (STO:CARA) Second Quarter 2025 Results
Key Financial Results
- Revenue: kr82.9m (up 26% from 2Q 2024).
- Net loss: kr5.51m (loss narrowed by 3.2% from 2Q 2024).
- kr0.08 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Carasent Earnings Insights
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden.
Performance of the Swedish Healthcare Services industry.
The company's shares are down 5.1% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Carasent's balance sheet.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:CARA
Carasent
Provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany.
Flawless balance sheet with reasonable growth potential.
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives
Strong DAU drives Ads and AI Data narrative

Silver X Has 152 Million Ounces, Already Producing and Its Biggest Growth Phase May Still Be Ahead

Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
NVIDIA will see a profit margin surge of 55% in the next 5 years
